Dr. Robert J. Lee, M.D.
Radiation Oncology (Radiation Oncology Physician)
3838 S 700 E, Suite 100
Salt Lake City, UT 84106
Who else practices at this address →
Salt Lake County includes primary care (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Emory University School of Medicine (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 246
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Emory University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Radiation Oncology Physician primary
UT license 188040-1205
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Intermountain Medical Center Murray, UT
- Intermountain Health Riverton Hospital Riverton, UT
- Lds Hospital Salt Lake City, UT
- Intermountain Health Alta View Hospital Sandy, UT
- Intermountain Health Heber Valley Hospital Heber City, UT
Medical groups
- Ihc Health Services Inc (3,960 clinicians)
- Utah Cancer Specialists PC (49 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 246
- Services billed
- 7,570
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Ct guidance for insertion of radiation therapy fields | 217 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 132 | 105 |
| Calculation of radiation therapy dose | 92 | 34 |
| Radiation treatment management, 5 treatment sessions | 78 | 35 |
| Design and construction of complex radiation treatment device | 66 | 36 |
| Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy | 62 | 16 |
| Complex radiation therapy planning | 45 | 43 |
| New patient office or other outpatient visit, 60-74 minutes | 42 | 42 |
| Design and construction of radiation treatment device for high precision radiation therapy | 28 | 26 |
| High precision radiation therapy planning | 26 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Salt Lake City, UT | 136 |
| Oxybutynin Chloride Er (oxybutynin chloride) Other prescribers in Salt Lake City, UT | 45 |
| Ciprofloxacin Hcl Other prescribers in Salt Lake City, UT | 43 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Salt Lake City, UT | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 10 payments worth $215 in total to this clinician.
| Merck Sharp & Dohme LLC | $47.60 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $45.18 |
| Novo Nordisk Inc | $44.80 |
| Pharmacosmos Therapeutics Inc. | $21.12 |
| Pfizer Inc. | $20.29 |
| Incyte Corporation | $18.88 |
| Boston Scientific Corporation | $17.06 |
| Food and Beverage | $215 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $700 in research payments for these studies, mostly to the institutions running them.
- A randomized phase ii trial of salvage radiotherapy with standard vs enhanced androgen deprivation therapy with enzalutamide in patients with postprostatectomy psa recurrences with aggressive disease features
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.